Ax­o­vant-turned-Sio ditch­es two re­main­ing pro­grams, lays off most em­ploy­ees and will seek a buy­er

A year and a half ago, Sio Gene Ther­a­pies at­tempt­ed to steer in­to a new his­to­ry, with then-CEO Pa­van Cheru­vu telling End­points News it was “not a vant any longer” af­ter break­ing away from the Ax­o­vant name, of the Roivant de­scent.

The com­pa­ny might be get­ting a re­brand again soon. That is: Sio is look­ing for a new own­er, or an­oth­er com­pa­ny to merge with as the biotech is shut­ter­ing work on its two re­main­ing pro­grams, for GM1 and GM2 gan­gliosi­do­sis, or Tay-Sachs and Sand­hoff dis­ease. SVB Se­cu­ri­ties will help the com­pa­ny find a new path for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER